Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Astria Therapeutics, Inc. (ATXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/12/2023 8-K Quarterly results
10/11/2023 8-K Quarterly results
03/31/2023 8-K Quarterly results
03/22/2023 8-K Quarterly results
02/02/2023 8-K Quarterly results
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Forward Looking Statements This presentation and various remarks we make during this presentation contain forward - looking statements of Astria Therapeutics, Inc . within the meaning of applicable securities laws and regulations, including statements with respect to : the Company’s projected cash runway and cash, cash equivalents and short - term investments as of 12 / 30 / 2022 ; expectations regarding the nature, timing and potential significance of the preliminary results from the Phase 1 a STAR - 0215 trial, the plans to add additional cohorts to the trial and the anticipated nature and timing of receipt of the data from such additional cohorts ; expectations regarding the timing of initiation, design and timing and nature of the anticipated proof of concept results from the planned P..."
12/15/2022 8-K Quarterly results
12/15/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
09/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Letter re: Prospectus Supplement to Registration Statement on Form S-3"
06/10/2022 8-K Quarterly results
02/22/2022 8-K Quarterly results
02/02/2022 8-K Quarterly results
12/15/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update"
09/08/2021 8-K Quarterly results
08/20/2021 8-K Quarterly results
06/30/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "OPEN MARKET SALE AGREEMENT SM",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3"
06/02/2021 8-K Quarterly results
04/16/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/29/2021 8-K Investor presentation
Docs: "Certificate of Designation of Series X Convertible Preferred Stock",
"Certificate of Designation of Series X Convertible Preferred Stock",
"STOCK PURCHASE AGREEMENT This Stock Purchase Agreement is dated as of January 28, 2021, by and among Catabasis Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on Annex A hereto . BACKGROUND: A. The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act , and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission under the Securities Act. B. The Purchasers, severally and not jointly, wish to purchase, and the Company wishes to issue and sell, upon the terms and conditions stated in this Agreement, an aggregate of 35,573 shares of Series X Convertible Preferred Stock, par value $0.001 per share , of the C...",
"Form of Registration Rights Agreement, by and among Catabasis Pharmaceuticals, Inc. and certain purchasers named therein",
"Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.",
"Presentation for investor conference call held by Catabasis Pharmaceuticals, Inc. on January 29, 2021"
12/07/2020 8-K Cost Associated with Exit or Disposal Activities
10/26/2020 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy"
09/21/2020 8-K Quarterly results
06/12/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated 2015 Stock Incentive Plan"
01/30/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and between the Company and Oppenheimer & Co. Inc",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering"
12/19/2019 8-K Quarterly results
10/16/2019 8-K Investor presentation
Docs: "Corporate slide presentation"
09/23/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/13/2019 8-K Quarterly results
07/31/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/05/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy